Results 171 to 180 of about 898,102 (296)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma. [PDF]

open access: yesClin Cancer Res, 2023
Ramos L   +19 more
europepmc   +1 more source

Epigenomic Cascades Across Organs in Metabolic Dysfunction–Associated Steatotic Liver Disease: New Therapeutic Horizons

open access: yesObesity Reviews, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disorder worldwide, affecting approximately one‐third of the population and increasing the risk of severe hepatic and cardiovascular complications.
Shurui Yang   +4 more
wiley   +1 more source

Translating gut microbiome research into therapies for type 1 diabetes

open access: yesExperimental Physiology, EarlyView.
Abstract Type 1 diabetes (T1D) is characterised by the loss of functional pancreatic β‐cells, for which lifelong insulin therapy remains the standard of care. Given that the gut microbiome can influence host health and that shifts in gut microbial profiles have been observed in T1D, growing interest has emerged in the role of the gut microbiome in T1D,
Shanti P. Kok   +2 more
wiley   +1 more source

Post‐exercise ketone supplementation improves endurance performance and mitochondrial adaptations during an 8‐week endurance training intervention

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Twenty‐eight trained males completed 8 weeks of supervised indoor cycling training, receiving post‐exercise and pre‐sleep ketone monoester (KE, n = 14) or isocaloric placebo (CON, n = 14). Both groups improved 30 min time‐trial performance with training, but KE achieved a 4% higher power output than CON at the end of the training
Ruben Robberechts   +8 more
wiley   +1 more source

Development, Live Birth and Fertility in Mouse Oocytes Penetrated by Spermatids Exposed to the HDAC Inhibitor Scriptaid. [PDF]

open access: yesReprod Med Biol
Watanabe S   +9 more
europepmc   +1 more source

Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications

open access: yesInternational Journal of Cancer, Volume 160, Issue 1, Page 7-23, 1 January 2027.
ABSTRACT Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...
Min Xing   +6 more
wiley   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, Volume 138, Issue 45, 2 November 2026.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +2 more sources

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy